Over the counter asthma treatments
Pro Research Analysisby 
Searched over 200M research papers
Over-the-Counter Asthma Treatments: Types and Availability
Over-the-counter (OTC) asthma treatments are primarily available for people with mild, intermittent asthma. In the United States, the most notable OTC inhaler is Primatene Mist, which contains epinephrine and is approved for use in individuals aged 12 and older. The administration technique for this inhaler has changed from its original version, but it remains the only widely available OTC inhaler for asthma relief in the U.S. market 110.
Short-Acting Beta-2 Agonists (SABA) and Epinephrine Inhalers: Usage and Risks
Short-acting beta-2 agonists (SABA), such as albuterol, are commonly used as reliever medications for asthma. However, in many countries, SABAs are only available by prescription, while OTC options like epinephrine inhalers are more accessible in the U.S. The use of OTC SABA and epinephrine inhalers is widespread, with prevalence rates of OTC SABA use ranging from 1.4% to 39.6% in different populations .
While occasional use of OTC epinephrine inhalers by individuals with mild, intermittent asthma is generally considered safe and effective, misuse or overuse can lead to severe adverse reactions, including death 310. Overuse of SABA or epinephrine inhalers is linked to poor asthma control, increased risk of asthma attacks, higher healthcare utilization, and even increased mortality 289. Many users of OTC relievers do not use preventer medications (such as inhaled corticosteroids), which further increases their risk of uncontrolled asthma and urgent healthcare needs 289.
Patient Behavior and Education: Challenges with OTC Asthma Medications
A significant proportion of people who purchase OTC asthma relievers overuse them, often using them more than twice per week, which is above recommended guidelines 28. Many of these individuals have moderate to severe asthma and do not use daily preventer medications, leading to suboptimal asthma control and increased risk of severe outcomes 28. Additionally, some individuals using OTC relievers may not have a formal asthma diagnosis, making it difficult to identify and manage this at-risk population .
Lack of understanding about the risks of SABA and epinephrine overuse is common, highlighting the need for better patient education and regular monitoring by healthcare providers 28. Improved education about asthma management and the importance of preventer medications could help reduce the negative consequences associated with OTC reliever overuse 289.
Alternatives and Evolving Guidelines: The Case for OTC Inhaled Corticosteroid/Formoterol
Recent asthma management guidelines recommend the use of inhaled corticosteroid (ICS)/formoterol combinations as both maintenance and reliever therapy, even for mild asthma, instead of relying solely on SABA or epinephrine 610. Evidence shows that as-needed ICS/formoterol reduces the risk of severe asthma exacerbations and mortality compared to SABA-only therapy 56. However, in the U.S., ICS/formoterol inhalers are not currently available OTC, limiting access to this safer and more effective option 56.
Cost-effectiveness analyses suggest that making budesonide-formoterol (an ICS/formoterol combination) available OTC would improve asthma outcomes, prevent fatalities, and be cost-saving, especially for underinsured populations 56. Experts argue that regulatory changes to allow OTC access to ICS/formoterol could significantly improve asthma care and reduce the risks associated with current OTC options like epinephrine 56.
Controversies and Policy Considerations
There is ongoing debate about expanding OTC access to asthma medications. Proponents argue that easier access could improve adherence and reduce barriers to treatment, especially for those who struggle with prescription costs or inconvenience . However, many professional organizations and experts caution that OTC availability of bronchodilators without proper education and monitoring could worsen asthma control, increase healthcare costs, and undermine guideline-based management 47.
Conclusion
OTC asthma treatments, such as epinephrine inhalers, provide quick relief for mild, intermittent asthma but carry significant risks if misused or overused, especially without concurrent use of preventer medications. Overuse is common and associated with poor asthma control and increased healthcare needs. Current guidelines favor ICS/formoterol combinations over SABA or epinephrine alone, but these are not yet available OTC in many countries. Improving patient education, regular monitoring, and considering safer OTC options could help address the challenges and risks associated with current OTC asthma treatments 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Safety of over-the-counter inhalers for asthma: report of the council on scientific affairs.
Over-the-counter epinephrine inhalers are safe and effective for mild, intermittent asthma when used according to label instructions, but misuse can cause severe adverse reactions, including death.
Cost-effectiveness of budesonide-formoterol versus inhaled epinephrine in United States adults with mild asthma.
OTC as-needed budesonide-formoterol for treating mild asthma in underinsured adults without HCP management improves asthma outcomes, prevents fatalities, and is cost-saving.
DOI